Home › Funds › Eversept Partners, LP › PHVS
Eversept Partners, LP position in PHVS
PHARVARIS N V · Health Care
Eversept Partners, LP reported holding 386,383 shares of PHVS (PHARVARIS N V) in its Q2 2026 13F filing — a position valued at US$13.4M, representing 0.70% of its reported portfolio and ranking #38 among its reported holdings. Eversept Partners, LP has disclosed PHVS holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Eversept Partners, LP's PHVS position evolved
Eversept Partners, LP first disclosed a stake in PHVS in Q4 2025 at 439,177 shares (US$12.2M). The position peaked in Q2 2026 at 386,383 shares, worth US$13.4M. Across 3 filings, Eversept Partners, LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 386,383 shares valued at US$13.4M — a reduction of -20,577 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 439.18K | $12.19M | New |
| Q1 2026 | 406.96K | $11.50M | Reduce |
| Q2 2026 | 386.38K | $13.36M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHVS and 13F data
PHVS (PHARVARIS N V) is a Health Care company. 49 other funds we track also report a position in PHVS — the largest reported positions include GENERAL ATLANTIC, L.P. (US$226.5M), Foresite Capital Management IV, LLC (US$165.2M), venBio Partners LLC (US$160.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHVS
- GENERAL ATLANTIC, L.P. 6.55M sh · $226.53M · Q2 2026
- Foresite Capital Management IV, LLC 4.78M sh · $165.24M · Q2 2026
- venBio Partners LLC 4.64M sh · $160.57M · Q2 2026
- EQT Fund Management S.a r.l. 3.42M sh · $118.42M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.38M sh · $116.74M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 2.68M sh · $92.52M · Q2 2026
- Commodore Capital LP 1.43M sh · $49.28M · Q2 2026
- Novo Holdings A/S 1.40M sh · $48.41M · Q2 2026
- Saturn V Capital Management LP 1.31M sh · $45.44M · Q2 2026
- TCG Crossover Management, LLC 1.01M sh · $34.86M · Q2 2026
- Sofinnova Investments, Inc. 881.30K sh · $30.48M · Q2 2026
- 5AM Venture Management, LLC 797.60K sh · $27.58M · Q2 2026
More on Eversept Partners, LP
FAQ
How long has Eversept Partners, LP held PHVS?
Eversept Partners, LP has disclosed PHVS holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Eversept Partners, LP's current position in PHVS?
As of Q2 2026, Eversept Partners, LP holds 386.38K shares of PHVS (PHARVARIS N V), valued at $13.36M, representing 0.70% of its reported portfolio and ranking #38.
Has Eversept Partners, LP been buying or selling PHVS?
In the latest 13F filing (Q2 2026), Eversept Partners, LP reduced its position in PHVS. The position peaked in Q2 2026 at 386.38K shares.
Which other funds hold PHVS?
Other major institutional holders of PHVS include GENERAL ATLANTIC, L.P., Foresite Capital Management IV, LLC, venBio Partners LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.